Abzena Ltd., of Cambridge, U.K., appointed Elaine Sapinoso senior vice president of global quality.

Amphivena Therapeutics Inc., of South San Francisco, appointed Victoria Smith chief scientific officer and Peter Van Vlasselaer independent executive chair of its board.

Antares Pharma nc., of Ewing, N.J., appointed Karen Smith to its board.

Cardiol Therapeutics Inc., of Oakville, Ontario, appointed Thomas Moffatt chief commercial officer.

Cerevance Inc., of Boston, appointed Lee A. Dawson vice president of neuroscience.

Confo Therapeutics NV, of Ghent, Belgium, appointed Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert to its scientific advisory board. Steyaert will serve as chair.

Constellation Pharmaceuticals Inc., of Cambridge, Mass., appointed Jessica Christo chief product development officer.

DBV Technologies Inc., of Montrouge, France, appointed Michel de Rosen non-executive chair of its board. CEO Daniel Tassé was appointed to the board and Pierre-Henri Benhamou will join its scientific advisory board.

Deciphera Pharmaceuticals Inc., of Waltham, Mass., appointed Steve Hoerter president and CEO.

Fluidigm Corp., of South San Francisco, appointed Colin McCracken chief commercial officer.

Fusion Pharmaceuticals Inc., of Hamilton, Ontario, appointed John J. Crowley chief financial officer.

Gradalis Inc., of Carrollton, Texas, appointed Luisa Manning vice president of medical and scientific affairs.

Inhibikase Therapeutics Inc., of Atlanta, appointed C. Warren Olanow, Karl D. Kieburtz and Robert A. Hauser to its scientific advisory board.

Kezar Life Sciences Inc., of South San Francisco, appointed Celia Economides senior vice president of strategy and external affairs.

Kiadis Pharma NV, of Amsterdam, appointed Dirk de Naeyer chief operations officer and Martine Nolan head of quality assurance.

Krystal Biotech Inc., of Pittsburgh, appointed Julian S. Gangolli to its board and nomination and governance committee.

Leo Science & Tech Hub, the Boston-based R&D innovation unit of Leo Pharma A/S, of Ballerup, Denmark, appointed Vladimir Morozov senior director of bioinformatics.

Mitsubishi Tanabe Pharma America Inc., of Jersey City, N.J., appointed Sam Shum vice president of operations and strategy.

Neurimmune AG, of Schlieren, Switzerland, appointed John Dellapa general counsel.

Novaremed AG, of Basel, Switzerland, appointed Nicholas Draeger CEO.

Oasmia Pharmaceutical AB, of Uppsala, Sweden, appointed Anette Sjödin executive vice president, effective June 1, and Maria Nilsson Hagberg head of regulatory affairs, effective April 18.

Phasebio Pharmaceuticals Inc., of Malvern, Pa., appointed Richard A. van den Broek to its board.

Rexahn Pharmaceuticals Inc., of Rockville, Md., appointed Lara S. Sullivan to its board and chair of its business development committee.

Sunovion Pharmaceuticals Inc., of Marlborough, Mass., appointed Antony Loebel president and CEO, effective April 1.

Tetra Bio-Pharma Inc., of Orleans, Ontario, appointed Aurelia De Pauw vice-president, clinical programs and medical affairs.

Urovant Sciences Ltd., of Basel, Switzerland, appointed James Robinson to its board.

Zafgen Inc., of Boston, appointed Priya Singhal head of research and development.